LUCD

Lucid Diagnostics Inc. (LUCD) | Rumor.io

Lucid Diagnostics

LUCD

Attention (50-day avg)0%

Attention rank (50-day avg)#1,427

Bullish sentiment (50-day avg)85%

Price to earnings ratio-1.87

Market capitalization153.9M

Earnings per share-0.41

Dividend yield (TTM)—

Revenue (annual)4.7M

Net income (annual)-58M

Social

What share of all stock conversation is about LUCD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Lucid Diagnostics Inc. (LUCD) expects to begin submitting Medicare claims under 0114U for Texas-processed tests this month, with a potential 1,000 tests monthly.
The California lab's MAC is MolDX-participating, so claims there await a final revised Local Coverage Determination from LUCD's pending reconsideration request.
The Texas facility's ability to process tests on a more certain reimbursement framework than the CA facility could lead to exponential growth in revenue, even without the now long overdue LCD approval.

Generated by AI

Sentiment

Of the messages about LUCD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40% -60	87.5% -3.41	82.22% -6.41	88.03% -2.72
Bearish	60% new	12.5% +3.41	17.78% +6.41	11.97% +2.72

Bullish· Jan 23

$LUCD has seen significant volume, driving the current move and indicating strong buying pressure.
Once Lucid Diagnostics receives Medicare coverage, its value is expected to spike, with analysts predicting prices of $4.00 to $9.00 or more.
The company's FDA approval and VA Medicare coverage have already been achieved, setting the stage for a significant increase in value and a potential 20x run-up to $15.00.

Bearish· Jan 21

The company has a history of experiencing significant price drops after initial gains, including four instances since January.
The recent news about the VA contract and CMS price tag may have been overpriced, leading to a negative market reaction.
The company's management is being criticized for its handling of the stock, with some investors expressing frustration and disappointment with the company's performance.

Generated by AI

Topics

Of the messages about LUCD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	63.52%
Technical Analysis	—	—	33.33%	10.97%
Controversies	—	—	0%	4.95%
Analysts	—	—	0%	17.77%
Earnings	—	—	0%	2.78%
Macro	—	—	0%	0%

Analysts· Nov 8

Analysts at BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics with "buy" ratings and price targets of $14 and $18, respectively.
Cantor Fitzgerald analyst Charles Duncan initiated coverage with an Overweight rating and $21 price target, while Needham initiated with a Buy rating and $17 price target.
BTIG analyst Mark Massaro and Canaccord Genuity analyst Kyle Mikson also initiated coverage with Buy ratings and price targets of $14 and $18, respectively.

Announcements· Jan 21

Lucid Diagnostics has been awarded a contract with the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test across the VA healthcare system, expanding access to esophageal precancer testing for over 9 million enrolled veterans annually.
The contract includes pre-negotiated pricing that matches the established Medicare payment rate, allowing VA hospitals nationwide to access EsoGuard through a single national procurement framework.
The estimated annual revenue to Lucid Diagnostics from this contract could range from $23 million to $155 million at steady state, assuming a gradual penetration rate of 1-5% of eligible veterans tested per year.

Generated by AI

Community

Of the messages about LUCD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.72%	92.54%	83.51%
Newcomers	0%	1.28%	7.46%	16.49%

Regulars· Sep 23

The Texas lab's Medicare Administrative Contractor (MAC) does not participate in MolDX, allowing LUCD to submit claims under 0114U for tests processed in Texas, which can process up to 1,000 tests monthly.
The potential for improved reimbursement, pending a revised Local Coverage Determination (LCD), is a positive development that bolsters revenue estimates, and a 12-month look-back period should allow billing for an estimated 2,000-3,000 Medicare-covered tests already performed.
The Texas lab's ability to process tests on a more certain reimbursable framework than the California facility may lead to exponential growth in revenue, and the company's derisking regarding dilution and cashflow issues may make this news nearly as good as LCD approval.

Newcomers· Jan 21

The recent contract awarded to Lucid Diagnostics for EsoGuard is a significant milestone, with the company expected to receive up to $190 million in future based income.
The contract has already led to a surge in price for PAVM, the parent company of Lucid Diagnostics, with a 250% increase, while Lucid Diagnostics itself saw a 7% drop, sparking concerns about pricing anomalies.
Investors are taking note of the potential for retroactive payments for up to 12 months, estimated at $10-$20 million, which could lead to a significant increase in revenue for Lucid Diagnostics.

Generated by AI

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.

7d agoYahoo Finance

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript

Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

1mo agoBenzinga

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

Lucid Diagnostics (NASDAQ:LUCD) is positioning its EsoGuard test as a non-invasive tool to identify Barrett’s Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a key Medicare coverage decision and expands relationships with commercial payers, the Department of Ve

1mo agoYahoo Finance

Also Discussed

Investors talking about LUCD also mention

#	Name	Attention
1	Pavmed Inc.PAVM	0%0
2	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
3	EXAS - Exact Sciences Corporation	——
4	PDS Biotechnology CorporationPDSB	0%-0.01
5	Beyond Air, Inc.XAIR	0%0
6	DMTK - DermTech, Inc.	——
7	X4 Pharmaceuticals, Inc.XFOR	0%0
8	EFTR - eFFECTOR Therapeutics, Inc.	——
9	ACHL - Achilles Therapeutics plc	——
10	NARI - Inari Medical, Inc.	——

Lucid Diagnostics Inc.

Healthcare
Medical Devices

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.

Website

Location

360 Madison Avenue

New York, NY, 10017

United States

Social

What share of all stock conversation is about LUCD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Lucid Diagnostics Inc. (LUCD) expects to begin submitting Medicare claims under 0114U for Texas-processed tests this month, with a potential 1,000 tests monthly.
The California lab's MAC is MolDX-participating, so claims there await a final revised Local Coverage Determination from LUCD's pending reconsideration request.
The Texas facility's ability to process tests on a more certain reimbursement framework than the CA facility could lead to exponential growth in revenue, even without the now long overdue LCD approval.

Generated by AI

Sentiment

Of the messages about LUCD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40% -60	87.5% -3.41	82.22% -6.41	88.03% -2.72
Bearish	60% new	12.5% +3.41	17.78% +6.41	11.97% +2.72

Bullish· Jan 23

$LUCD has seen significant volume, driving the current move and indicating strong buying pressure.
Once Lucid Diagnostics receives Medicare coverage, its value is expected to spike, with analysts predicting prices of $4.00 to $9.00 or more.
The company's FDA approval and VA Medicare coverage have already been achieved, setting the stage for a significant increase in value and a potential 20x run-up to $15.00.

Bearish· Jan 21

The company has a history of experiencing significant price drops after initial gains, including four instances since January.
The recent news about the VA contract and CMS price tag may have been overpriced, leading to a negative market reaction.
The company's management is being criticized for its handling of the stock, with some investors expressing frustration and disappointment with the company's performance.

Generated by AI

Topics

Of the messages about LUCD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	63.52%
Technical Analysis	—	—	33.33%	10.97%
Controversies	—	—	0%	4.95%
Analysts	—	—	0%	17.77%
Earnings	—	—	0%	2.78%
Macro	—	—	0%	0%

Analysts· Nov 8

Analysts at BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics with "buy" ratings and price targets of $14 and $18, respectively.
Cantor Fitzgerald analyst Charles Duncan initiated coverage with an Overweight rating and $21 price target, while Needham initiated with a Buy rating and $17 price target.
BTIG analyst Mark Massaro and Canaccord Genuity analyst Kyle Mikson also initiated coverage with Buy ratings and price targets of $14 and $18, respectively.

Announcements· Jan 21

Lucid Diagnostics has been awarded a contract with the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test across the VA healthcare system, expanding access to esophageal precancer testing for over 9 million enrolled veterans annually.
The contract includes pre-negotiated pricing that matches the established Medicare payment rate, allowing VA hospitals nationwide to access EsoGuard through a single national procurement framework.
The estimated annual revenue to Lucid Diagnostics from this contract could range from $23 million to $155 million at steady state, assuming a gradual penetration rate of 1-5% of eligible veterans tested per year.

Generated by AI

Community

Of the messages about LUCD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.72%	92.54%	83.51%
Newcomers	0%	1.28%	7.46%	16.49%

Regulars· Sep 23

The Texas lab's Medicare Administrative Contractor (MAC) does not participate in MolDX, allowing LUCD to submit claims under 0114U for tests processed in Texas, which can process up to 1,000 tests monthly.
The potential for improved reimbursement, pending a revised Local Coverage Determination (LCD), is a positive development that bolsters revenue estimates, and a 12-month look-back period should allow billing for an estimated 2,000-3,000 Medicare-covered tests already performed.
The Texas lab's ability to process tests on a more certain reimbursable framework than the California facility may lead to exponential growth in revenue, and the company's derisking regarding dilution and cashflow issues may make this news nearly as good as LCD approval.

Newcomers· Jan 21

The recent contract awarded to Lucid Diagnostics for EsoGuard is a significant milestone, with the company expected to receive up to $190 million in future based income.
The contract has already led to a surge in price for PAVM, the parent company of Lucid Diagnostics, with a 250% increase, while Lucid Diagnostics itself saw a 7% drop, sparking concerns about pricing anomalies.
Investors are taking note of the potential for retroactive payments for up to 12 months, estimated at $10-$20 million, which could lead to a significant increase in revenue for Lucid Diagnostics.

Generated by AI

Lucid Diagnostics

Social

Sep 23

Bullish· Jan 23

Bearish· Jan 21

Analysts· Nov 8

Announcements· Jan 21

Regulars· Sep 23

Newcomers· Jan 21

Lucid Diagnostics advances Medicare payment pathways for tests

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

Also Discussed

Lucid Diagnostics Inc.

Company Information

Location

Lucid Diagnostics advances Medicare payment pathways for tests

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

Also Discussed

Social

Sep 23

Bullish· Jan 23

Bearish· Jan 21

Analysts· Nov 8

Announcements· Jan 21

Regulars· Sep 23

Newcomers· Jan 21